Fairmount Funds Management LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 3:45 pm Unchanged |
2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 3,202,798 6.600% |
0 (Unchanged) |
Filing |
| 2024-11-14 4:15 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 3,202,798 6.800% |
1,071,429 (+50.27%) |
Filing |
| 2024-02-14 3:45 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 2,131,369 5.200% |
6,744 (+0.32%) |
Filing |
| 2023-04-27 10:00 am Purchase |
2023-04-18 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 2,124,625 5.170% |
2,124,625 (New Position) |
Filing |